In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

US Biosimilars: Busting Blockbusters Or Managing Obsolescence?

As a new generation of biosimilars challenge some of pharma’s biggest-selling products, this In Vivo analysis looks at how the originator blockbuster might fare in the face of competition. Experience in Europe, which predates that in the US by about a decade, provides a number of crucial pointers to outcomes and defensive strategies.

Biosimilars Biologics Life Cycle Management
Advertisement

Latest From Market Intelligence

Deals In Depth: April 2017

Janssen got development and commercialization rights to PeptiDream's macrocyclic/constrained peptides in cardio-metabolic diseases; BD added to its strong position in medication management and infection prevention through the $23 billion takeover of Bard. A nearly $2 billion IPO by Galenica Sante helped boost biopharma financing.

Deals BioPharmaceutical

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics

In Vivo's Deals Of The Month, May 2017

In Vivo's editors pick May's most significant deals, including Thermo Fisher's bid for Patheon and Merck's tie-up with Teijin. (Free article.)

Deals BioPharmaceutical

Innovation In Oncology: An Infographic

Oncology innovation: lots of drugs, lots of trials, sometimes not enough patients. And styles of innovation depend on whether a company has a big franchise to defend or would like one. In Vivo presents current data on sales, pipelines, trials and fails. (Free article.)

BioPharmaceutical Cancer

Biopharma Quarterly Deal-Making Statistics, Q1 2017

Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.

BioPharmaceutical Deals
See All
UsernamePublicRestriction

Register